DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Rating of “Moderate Buy” from Analysts

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has been given an average rating of “Moderate Buy” by the six research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $12.3333.

DMAC has been the subject of a number of recent research reports. Lake Street Capital reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a research report on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, January 21st.

DiaMedica Therapeutics Stock Down 0.9%

Shares of DMAC stock opened at $6.79 on Friday. The stock has a market capitalization of $353.62 million, a PE ratio of -9.56 and a beta of 1.09. DiaMedica Therapeutics has a 52-week low of $3.19 and a 52-week high of $10.42. The stock’s 50-day moving average price is $7.90 and its 200 day moving average price is $7.66.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several institutional investors have recently bought and sold shares of the company. Royal Bank of Canada raised its position in DiaMedica Therapeutics by 46,879.1% during the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock worth $588,000 after buying an additional 154,701 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of DiaMedica Therapeutics by 76.7% in the first quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock valued at $462,000 after acquiring an additional 52,854 shares in the last quarter. Jane Street Group LLC increased its stake in shares of DiaMedica Therapeutics by 138.5% during the first quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock worth $382,000 after acquiring an additional 58,457 shares during the period. Geode Capital Management LLC raised its holdings in DiaMedica Therapeutics by 99.6% during the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after purchasing an additional 314,407 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in DiaMedica Therapeutics during the second quarter worth about $29,000. 10.12% of the stock is owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.